New aspects of treatment and prophylaxis of gastrointestinal side effects caused by nonsteroidal-antiinflammatory drugs (NSAIDs);Neue aspekte in behandlung und prophylaxe gastrointestinaler nebenwirkungen durch nicht-steroidale antiphlogistika (NSA)

Zeitschrift fur Rheumatologie

Volumn 58, Issue 4, 1999, Pages 173-184

  Braun, J ^a   Sieper, J ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

COX 2 selectivity; Non steroidal antiinflammatory drugs; NSAID gastropathy

Indexed keywords

ARTHROTEC; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOPROFEN; MELOXICAM; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; UNCLASSIFIED DRUG;

DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MIXTURE; DRUG SELECTIVITY; DYSPEPSIA; HUMAN; REVIEW; RHEUMATIC DISEASE; STOMACH PROTECTION; STOMACH ULCER;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENAL ULCER; FEMALE; GASTRITIS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STOMACH ULCER;

EID: 0032881186     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930050168     Document Type: Review

References (52)

1. Singh G, Rosen Ramey D (1998) NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 51:8-16
2. Blum AL, Bolten WW, Labenz J, Stolte M, Rösch W (1998) Therapie und Prävention des ASS- und NSAR-Ulkus. Dtsch Ärztebl 95:348
3. Graham DY, Smith JL (1988) Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol 83:1081-1084
4. Lichtensiein DR, Syngal S, Wolfe MM (1995) Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 38:5-18
5. Ehsanullah RS, Page MC, Tildesley G (1988) Wood JR Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 297:1017-1021
6. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF (1996) Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1156:1530-1536
7. Brooks PM, Day RO (1991) Nonsteroidal antiinflammatory drugs-differences and similarities. N Engl J Med 324: 1716-1725
8. Bjorkman D (1998) Non-steroidal antiinflammatory drug-associated toxicity of the liver, lower gastrointestinal tract and esophagus. Am J Med 105:17-21
9. Evans JM, McMahon AD, Murray FE, McDevitt DG, McDonald TM (1997) Nonsteroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 40:619-622
10. Hardin JG, Longenecker GL (1992) Handbook of drug therapy in rheumatic disease. Pharmacologic and clinical aspects. Boston, Little, Brown Co
11. Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A metaanalysis. Ann Intern Med 115:787-796
12. Garcia Rodriguez, LA, Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:769-772
13. Fries JF, Williams CA, Bloch DA (1991) The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum 34:1353-60
14. Piper JM, Ray WA, Daugherty JR, Griffin MR (1991) Corticosteroid use and peptic ulcer disease: role of nonsteroidalanti-inflammatory drugs. Ann Intern Med 114:735-740
15. Hochain P, Berkelmans I, Czernichow P, Duhamel C, Tranvouez JL, Lerebours E, Colin R (1995) Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol 7:419-426
16. irwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333:142-6
17. Reid IR (1997) Steroid-induced osteoporosis. Osteoporos Int 7 Suppl 3:S213-216
18. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, Dequeker J, Isomaki H, Littlejohn G, Mau J, Papazoglou S (1998) Gastrointestinal tolerability of meloxicam compared to diclofenac inosteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 37: 937-945
19. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, Isomaki H, Littlejohn G, Mau J Papazoglou S (1998) Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 37:946-951
20. Dougados M, Guegue A, Nakache JP, Velicitat P, Veys EA, Nakache JP, Velicitat P, Veys M, Zeidler H, Calin A (1999) Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 38:235-244
21. Amor B, Dougados M et al (1995) Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 21: 117-128
22. Hansen TM, Matzen P, Madsen P (1984) Endoscopic evaluation of the effect of indomethacin capsules and suppositories on the gastric mucosa in rheumatic patients. J Rheumatol 11:484-487
23. Taha AS, Hudson N, Hawkey CJ, Swanell AJ, Tryre PN, Cottrell J, Mann SG, Simon TJ, Sturrock R, Russell RI (1996) Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammalory drugs. New Engl J Med 334:1435-1439
24. Graham DJ, White RH, Moreland LW et al (1993) Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAID. Ann Int Med 119:257-262
25. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:241-249
26. Maetzel A, Ferraz MB, Bombardier C (1998) The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 41:16-25
27. McKenna F (1998) Diclofenac/misoprostol: the European clinical experience. J Rheumatol Suppl 51:21-30
28. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719-726
29. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727-734
30. Tamblyn R, Berkson L, Dauphinee WD, Gayton D, Grad R, Huang A, Isaac L, McLeod P, Snell L (1997) Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 127: 429-438
31. Herxheimer A (1998) Many NSAID users who bleed don't know when to stop. BMJ Feb 14; 316:492
32. Braun J, Sieper J (1996) The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 8:275-787
33. Hawkey CJ (1996) In: Helicobacter pylori: basic research to clinical cure. Hunt RH, Tygat GNJ, eds. Kluwer Academic, London. Chapter 32
34. Veldhuyzen van Zanten SJO (1997) Bleeding ulcers, interaction between NSAIDs and Helicobacter pylori infection, and nonulcer dyspepsia. Gastroenterology 113:90
35. Schubert TT, Bologna SD, Nensey Y, Schubert AB, Mascha EJ, Ma CK (1993) Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med 94:413-418
36. Chan FK, Sung JJ, Chung SC, Tu KF, Yung MY, Leung VK, Lee YT, Chan CS, Li FK, Woo J (1997) Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350:975-979
37. Vane J (1994) Towards a better aspirin. Nature 367:215-216
38. Brune K, Hinz B (1998) Zum aktuellen Stand der Zyklooxygenase-Forschung. Dt Ärztebl 95:A-348-354 (7)
39. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P (1998) Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 41:122-129
40. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Creminon C, Madouf J et al (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271:1705-1712
41. Cryer B, Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104:413-421
42. Distel M, Mueller C, Bluhmki E, Fries J (1996) Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 35 Suppl 1:68-77
43. Picot D, Loll PJ, Garavito RM (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367:243-249
44. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 3:927-933
45. Geis GS, Stead H, Morant S, Naudin R, Hubbard RC (1998) Efficacy and safety of Celocoxib, a specific COX-2-inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 41(suppl):316 abst. 1699
46. Cannon G, Caldwell J, Holt P, McLean B, Zeng Q, Ehrich E, Seidenberg B, Bolognese J, Daniels B (1998) MK-0966, a specific COX-2-inhibitor, has clinical efficacy comparable to Diclofenac in the treatment of knee and hip osteoarthritis in a 26 week controlled clinical trial. Arthritis Rheum 41(suppl):196 abst. 983
47. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM et al (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378:406-409
48. Lungenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD et al (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483- 492
49. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, MacNaughton WK (1998) Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 115:101-109
50. Zimmermann KC, Sarbia M, Schrör K, Weber AA (1998) Constitutive Cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 54:536-540
51. Kalkutgar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ (1998) Aspirin-like molecules that covalently inactivate cyclooxygenase-21211. Science 280:1268-1270
52. Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of non-steroidal antiinflammatory drugs. New Engl J Med 340:1888-1899